Dr. Kelly Huang Ph.D. Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Dr D OBLN stock SEC Form 4 insiders trading

Dr has made over 2 trades of the Obalon Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 3,200 units of OBLN stock worth $50,496 on 9 May 2014.

The largest trade he's ever made was buying 3,200 units of Obalon Therapeutics Inc stock on 9 May 2014 worth over $50,496. On average, Dr trades about 711 units every 0 days since 2014. As of 9 May 2014 he still owns at least 3,200 units of Obalon Therapeutics Inc stock.

You can see the complete history of Dr Huang stock trades at the bottom of the page.

Dr. Kelly Huang Ph.D. biography

Dr. Kelly Huang Ph.D. is the Consultant at Obalon Therapeutics Inc.

What is the salary of Dr D?

As the Consultant of Obalon Therapeutics Inc, the total compensation of Dr D at Obalon Therapeutics Inc is $800,112. There are no executives at Obalon Therapeutics Inc getting paid more.

How old is Dr D?

Dr D is 51, he's been the Consultant of Obalon Therapeutics Inc since . There are 9 older and 4 younger executives at Obalon Therapeutics Inc. The oldest executive at Obalon Therapeutics Inc is Raymond Dittamore, 73, who is the Independent Director.

Insiders trading at Obalon Therapeutics Inc

Over the last 8 years, insiders at Obalon Therapeutics Inc have traded over $0 worth of Obalon Therapeutics Inc stock and bought 3,260,355 units worth $6,939,913 . The most active insiders traders include Parters Vii L Pblair James ..., Partners X Lp Inter West Ma..., and David Moatazedi. On average, Obalon Therapeutics Inc executives and independent directors trade stock every 54 days with the average trade being worth of $432,771. The most recent stock trade was executed by William J. Plovanic on 12 November 2019, trading 65,000 units of OBLN stock currently worth $107,900.

What does Obalon Therapeutics Inc do?

Obalon Therapeutics, Inc. is a San Diego-based company focused on developing and commercializing novel technologies for weight loss.

Obalon Therapeutics Inc executives and stock owners

Obalon Therapeutics Inc executives and other stock owners filed with the SEC include:

• Dr. Kelly Huang Ph.D.,
  Consultant
• Andrew Rasdal,
  Chairman of the Board, President, Chief Executive Officer
• Andrew P. Rasdal,
  CEO, Pres & Director
• Sharon Stevenson,
  Independent Director
• Lesley Howe,
  Independent Director
• Douglas Fisher,
  Independent Director
• Raymond Dittamore,
  Independent Director
• William Plovanic,
  Director
• Robert MacDonald,
  Chief Retail Officer
• Donald Young,
  Vice President of Quality Assurance
• Todd Wood,
  Vice President - Global Sales
• Lisa Metzner,
  Vice President of Marketing
• Matthew Norwood,
  Vice President of Sales
• Steve Johnson,
  Vice President - Operations
• Nooshin Hussainy,
  Chief Financial Officer
• Nooshin Hussainy,
  CFO & Sec.
• Kim P. Kamdar,
  
• Erin Morisey,
  VP Strategic Partnerships
• Partners X Lp Inter West Ma...,
  
• David Moatazedi,
  
• Vii Associates Lpblair Jame...,
  
• Parters Vii L Pblair James ...,
  
• Amy Vanden Berg,
  Chief Clinical & Reg Officer
• Kelly Huang,
  Pres & Chief Executive Officer
• Robert H Jr Mondore,
  VP of Operations
• Jonah Shacknai,
  
• Partners X Lp Inter West Ma...,
  
• Daina Schmidt,
  Vice President of Marketing
• Mark Brister,
  Chief Technology Officer